文献速递慢性静脉疾病

使用ClariVein和液态聚多卡醇行机械化学消融治疗大隐静脉功能不全的多中心随机剂量探索研究

A multicenter, randomized, dose-finding study of mechanochemical ablation using ClariVein and liquid polidocanol for great saphenous vein incompetence.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-11-12

本多中心、随机、对照、单盲试验将364例(375条肢体)症状性原发性大隐静脉主干功能不全患者随机分配至机械化学消融联合2%或3%液态聚多卡醇组,随访6个月。3%组6个月技术成功率78.0%高于2%组的69.8%(P=0.027),但两组生活质量差异无统计学意义。

要点

  • 3%聚多卡醇组6个月技术成功率为78.0%,高于2%组的69.8%(P=0.027)。
  • 静脉直径≤5.9 mm者总体技术成功率84.3%,高于>5.9 mm者的59.5%(P<0.001)。
  • 3%组浅静脉血栓发生率高于2%组(18例 vs 8例,P=0.033)。

核心结论

  • 6个月随访时,使用3%液态聚多卡醇的机械化学消融成功率高于使用2%液态聚多卡醇者。
  • 两组生活质量差异无统计学意义。
  • 需要长期随访研究来探讨这些结果未来能否维持。

研究设计与样本

  • 多中心、随机、对照、单盲试验,随访6个月。
  • 纳入2012年至2018年的364例患者(375条肢体),189条肢体随机分配至2%组,186条肢体分配至3%组。
  • 纳入对象为症状性原发性大隐静脉主干功能不全患者,随机接受机械化学消融联合2%或3%液态聚多卡醇治疗。

主要发现

  • 6个月技术成功率2%组为69.8%,3%组为78.0%(P=0.027)。
  • 大隐静脉直径≤5.9 mm者总体技术成功率为84.3%,>5.9 mm者为59.5%(P<0.001)。
  • 6个月替代技术成功率2%组为61.4%,3%组为67.7%(P=0.028)。
  • 两组静脉临床严重程度评分、Aberdeen静脉曲张问卷评分及大多数简表36项健康调查问卷领域均改善(P<0.002)。
  • 术后疼痛轻;发生2例肺栓塞和2例深静脉血栓;浅静脉血栓在3%组发生更多(18例 vs 2%组8例;P=0.033)。

关键数值与推荐

  • 技术成功定义为治疗静脉段开放部分长度≤10 cm。
  • 替代技术成功定义为治疗静脉段闭塞≥85%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of the present study was to identify the ideal polidocanol (POL) concentration for mechanochemical ablation (MOCA) of the great saphenous vein (GSV) using the ClariVein system (Merit Medical, South Jordan, Utah). METHODS: We performed a multicenter, randomized, controlled, single-blind trial with a follow-up period of 6 months. Patients with symptomatic primary truncal GSV incompetence were randomized to MOCA + 2% POL liquid (2% group) or MOCA + 3% POL liquid (3% group). The primary outcome was technical success (TS), defined as an open part of the treated vein segment of ≤10 cm in length. The secondary outcomes were alternative TS, defined as ≥85% occlusion of the treated vein segment, postoperative pain, venous clinical severity scores, Aberdeen varicose vein questionnaire scores, and short-form 36-item health survey questionnaire scores, and complications. RESULTS: From 2012 to 2018, 364 patients (375 limbs) were included, of which, 189 limbs were randomly allocated to the 2% group and 186 to the 3% group. The TS rate at 6 months was 69.8% in the 2% group vs 78.0% in the 3% group (P = .027). A higher overall TS rate was seen in GSVs of ≤5.9 mm compared with GSVs >5.9 mm (84.3% vs 59.5%, respectively; P < .001). The alternative TS rate at 6 months was 61.4% in the 2% group and 67.7% in the 3% group (P = .028). The venous clinical severity scores, Aberdeen varicose vein questionnaire scores, and most short-form 36-item health survey questionnaire domains had improved in both groups (P < .002). Postprocedural pain was low. Two pulmonary embolisms and two deep vein thromboses were seen. Superficial venous thrombosis had occurred more often in the 3% group (18 vs 8 in the 2% group; P = .033). CONCLUSIONS: The results from the present study showed a higher success rate for MOCA with 3% POL liquid than for MOCA with 2% POL liquid at 6 months of follow-up. However, the difference in quality of life was not significant. Long-term follow-up studies are required to investigate whether these results will be sustained in the future.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Lam YL, Alozai T, Schreve MA, et al. A multicenter, randomized, dose-finding study of mechanochemical ablation using ClariVein and liquid polidocanol for great saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34781008. doi:10.1016/j.jvsv.2021.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。